Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-14. Numbers and descriptions here follow the published literature rather than marketing material.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Natural dried, not calcinated diatomaceous earth is regularly used in livestock nutrition research as a source of acid-insoluble ash (AIA), which is used as an indigestible marker. By measuring the content of AIA relative to nutrients in test diets and feces or digesta sampled from the terminal ileum (last third of the small intestine) the percentage of that nutrient digested can be calculated using the following equation:
== History == In 1905, Paul Carnot proposed the idea that a hormone regulates the production of red blood cells. After conducting experiments on rabbits subject to bloodletting, Carnot and his graduate student Clotilde-Camille Deflandre attributed an increase in red blood cells in rabbit subjects to a hemotropic factor called hemopoietin. Eva Bonsdorff and Eeva Jalavisto called the hemopoietic substance 'erythropoietin'. K.R. Reissman and Allan J. Erslev demonstrated that a certain substance, circulated in the blood, is able to stimulate red blood cell production and increase hematocrit. This substance was purified and confirmed as erythropoietin. In 1977, Goldwasser and Kung purified EPO. Pure EPO allowed the amino acid sequence to be partially identified and the gene to be isolated. Synthetic EPO was first successfully used to correct anemia in 1987. In 1985, Lin et al isolated the human erythropoietin gene from a genomic phage library and used it to produce EPO. In 1989, the US Food and Drug Administration (FDA) approved the hormone Epogen for use in certain anemias. Gregg L. Semenza and Peter J. Ratcliffe studied the EPO gene and its oxygen-dependent regulation. Along with William Kaelin Jr., they were awarded the 2019 Nobel Prize in Physiology or Medicine for their discovery of hypoxia-inducible factor (HIF), which regulates the EPO gene, as well as other genes, in response to hypoxia.
The advantage of diamorphine over morphine is that diamorphine is more fat soluble and therefore more potent by injection, so smaller doses of it are needed for the same effect on pain. Both of these factors are advantageous if giving high doses of opioids via the subcutaneous route, which is often necessary for palliative care. It is also used in the palliative management of bone fractures and other trauma, especially in children. In the trauma context, it is primarily given by nose in hospital; although a prepared nasal spray is available, it has traditionally been made by the attending physician, generally from the same "dry" ampoules as used for injection. In children, Ayendi nasal spray is available at 720 micrograms and 1600 micrograms per 50 microlitres actuation of the spray, which may be preferable as a non-invasive alternative in pediatric care, avoiding the fear of injection in children.
These physiological changes in the decomposers also alter the local environment in a way that allows certain minerals to be deposited, while others remain in solution. Generally, however, a fossilizing egg's shell keeps the same calcite it had in life, which allows scientists to study its original structure millions of years after the developing dinosaur hatched or died. However, eggs can also sometimes be altered after burial. This process is called diagenesis. One form of diagenesis is a microscopic cross-hatched pattern imposed on the eggshell by the pressure of being buried deeply. If the pressure gets severe enough, sometimes the eggshell's internal microscopic structure can be completely destroyed. Diagenesis can also happen chemically in addition to physically. The chemical conditions of a decomposing egg can make it easy for silica to be incorporated into eggshell and damage its structure. When iron-bearing substances alter eggshell it can be obvious because compounds like hematite, pyrite, and iron sulfide can turn the shell blackish or rusty colors.
=== Mechanism of action === Lumateperone acts as an antagonist at 5-HT2A receptors and binds to several dopamine receptors (D1, D2, and D4) with moderate affinity. It has moderate serotonin transporter reuptake inhibition, which is partly responsible for its antidepressant effect in bipolar disorder and reduction of negative symptoms of schizophrenia. It may also inhibit dopamine transporter reuptake, but more evidence is needed to confirm this. It has additional off-target antagonism at α1 receptors, without appreciable antimuscarinic or antihistaminergic properties, limiting side effects associated with other atypical antipsychotics, notably metabolic syndrome and hyperprolactinemia. Similar to aripiprazole, lumateperone acts as a partial agonist at inhibitory D2 autoreceptors and an antagonist at postsynaptic D2 receptors, thereby simultaneously reducing dopamine release and binding to postsynaptic receptors, respectively. However, lumateperone only occupies around 39% of D2 receptors—compared to at least 60-80% D2 occupancy for most antipsychotics to work for psychosis—and displays regioselectivity for the mesolimbic pathway, whose hyperactivity is responsible for the positive symptoms of schizophrenia. These qualities reduce the risk of extrapyramidal symptoms (EPS) from reduced dopaminergic transmission in the nigrostriatal pathway. A mechanism that is shared by all other atypical antipsychotics is antagonism of 5HT2A receptors, but, uniquely, lumateperone's affinity for these receptors is 60x higher than its affinity for D2 receptors.
Sources: en.wikipedia.org
== Energy release == The Q value is defined as the total energy released in a given nuclear decay. In beta decay, Q is therefore also the sum of the kinetic energies of the emitted beta particle, neutrino, and recoiling nucleus. (Because of the large mass of the nucleus compared to that of the beta particle and neutrino, the kinetic energy of the recoiling nucleus can generally be neglected.) Beta particles can therefore be emitted with any kinetic energy ranging from 0 to Q. A typical Q is around 1 MeV, but can range from a few keV to a few tens of MeV. Since the rest mass of the electron is 511 keV, the most energetic beta particles are ultrarelativistic, with speeds very close to the speed of light. In the case of 187Re, the maximum speed of the beta particle is only 9.8% of the speed of light. The following table gives some examples:
== Treatment == Treatment is focused on reducing stroke episodes and damage from a distending artery. Four treatment modalities have been reported in the treatment of vertebral artery dissection. The two main treatments involve medication: anticoagulation (using heparin and warfarin) and antiplatelet drugs (usually aspirin). More rarely, thrombolysis (medication that dissolves blood clots) may be administered, and occasionally obstruction may be treated with angioplasty and stenting. No randomized controlled trials have been performed to compare the different treatment modalities. Surgery is only used in exceptional cases.
Somapacitan, sold under the brand name Sogroya, is a growth hormone medication. Somapacitan is a human growth hormone analog. Somapacitan-beco is produced in Escherichia coli by recombinant DNA technology. The most common side effects include: back pain, joint pain, indigestion, a sleep disorder, dizziness, tonsillitis, swelling in the arms or lower legs, vomiting, adrenal insufficiency, hypertension, increase in blood creatine phosphokinase (a type of enzyme), weight increase, and anemia. It was approved for medical use in the United States in August 2020, and in the European Union in March 2021. Somapacitan is the first human growth hormone (hGH) therapy that adults only take once a week by injection under the skin; other FDA-approved hGH formulations for adults with growth hormone deficiency must be administered daily. It contains a small non-covalent moiety that reversibly binds to serum albumin which slows down elimination.
The Tahitians (Tahitian: Māʼohi; French: Tahitiens) are the Indigenous Polynesian people of Tahiti and thirteen other Society Islands in French Polynesia. The numbers may also include the modern population in these islands of mixed Polynesian and French ancestry (French: demis). Indigenous Tahitians are one of the largest Polynesian ethnic groups, behind the Māori, Samoans and Hawaiians.
Ants form symbiotic associations with a range of species, including other ant species, other insects, plants, and fungi. They also are preyed on by many animals and even certain fungi. Some arthropod species spend part of their lives within ant nests, either preying on ants, their larvae, and eggs, consuming the food stores of the ants, or avoiding predators. These inquilines may bear a close resemblance to ants. The nature of this ant mimicry (myrmecomorphy) varies, with some cases involving Batesian mimicry, where the mimic reduces the risk of predation. Others show Wasmannian mimicry, a form of mimicry seen only in inquilines.
Sources: en.wikipedia.org
== Examples of CGRP inhibitors == Small molecule CGRP antagonists are generally administered by mouth as pills. One type is a nasal spray. In contrast, CGRP monoclonal antibodies involve large molecules which must be given intravenously or as injections. Injections can be self-administered with an automatic pen monthly or quarterly, depending on the drug.
In sponges, the mesenchyme is called mesohyl. In diploblasts (Cnidaria and Ctenophora), the mesenchyme is fully ectodermally derived. This kind of mesenchyme is called ectomesodermal, and is not considered true mesoderm. In triploblastic acoelomates (such as flatworms), the term parenchyma is sometimes used for the middle (mesenchymal) layer, in which the dense layer includes tissues derived from both ectoderm, and entomesoderm (true mesoderm, derived from entoderm). When cellular material is sparse or densely packed, as in cnidarians, the mesenchyme may sometimes be called collenchyma, or parenchyma in flatworms. When no cellular material is present as in Hydrozoa, the layer is properly called mesoglea. In some colonial cnidarians, the mesenchyme is perforated by gastrovascular channels continuous among colony members. This entire matrix of common basal material is called coenenchyme.
== Signs and symptoms of diabetes mellitus == Symptoms of prediabetes – prediabetes typically has no distinct signs or symptoms. Patients should monitor for signs and symptoms of type 2 diabetes mellitus (see below).
In Berezovka, a memorial steel was erected in 1972. In Bychivka Station: A memorial plaque was dedicated in 1965. In Dubrova: a Monument was erected in 1979 commemorating the 1943 raid on the local German Garrison.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.